Press Releases

New preclinical data suggests PBI-4547 displays pleiotropic activities and has been shown to reduce non-alcoholic steatohepatitis (NASH), diabetes and fibrosis in different rodent models. LAVAL,...

Name change to Liminal BioSciences Inc. Divestment of UK bioseparations subsidiary to KKR for up to GBP 45 million in gross proceeds, of which GBP 32 million to be received upon closing Net loss...

LAVAL, QC, ROCKVILLE, MD and CAMBRIDGE, UK – November 11, 2019 – Liminal BioSciences Inc. (TSX: LMNL, OTCQX: PFSCF) (“Liminal BioSciences" or the "Company"), a clinical-stage...

LAVAL, QC, ROCKVILLE, MD and CAMBRIDGE, UK – November 11, 2019 – Liminal BioSciences Inc. (TSX: LMNL, OTCQX: PFSCF) (“Liminal BioSciences” or the “Company”), a biopharmaceutical...

LAVAL, QC, ROCKVILLE, MD and CAMBRIDGE, UK – November 4, 2019 – Liminal BioSciences Inc. (TSX: LMNL, OTCQX: PFSCF) (“Liminal BioSciences” or the “Company”), a clinical-stage...